Lupin gets approval from Health Canada for hypertension drugs
Pharma major Lupin on Friday announced that it has received approval for its Propranolol Hydrochloride extended-release (ER) capsules in 60 mg, 80 mg, 120 mg and 160 mg from Health Canada. The capsules will be used for the treatment of hypertension and prophylaxis of angina pectoris. Lupin is the first generic company to receive an approval of Pfizer Canada ULC’s Generic Inderal-LA capsules, the company said in a statement.The product will be manufactured from Lupin’s Pithampur unit-2 facility. As per IQVIA MAT December 2018 data, Propranolol Hydrochloride ER capsules had an annual sales of approximately CAD 8.6 million, the company said.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
